Experienced in Synovial Sarcoma

Christoph Schliemann

Muenster, NW, DE 
Experienced in Synovial Sarcoma
Muenster, NW, DE 
OverviewLocationsClinical Research

Overview

Christoph Schliemann practices in Muenster, Germany. Mr. Schliemann is rated as an Experienced expert by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Necrosis, Adult Soft Tissue Sarcoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 151 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Synovial Sarcoma.

Gender
Male

Locations

Muenster, NW, Germany
Other Locations
Essen, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: April 20, 2022
Intervention Type: Drug
Study Drugs: F16IL2, BI 836858
Study Phase: Phase 1
Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Drug
Study Drugs: L19TNF?, Doxorubicin
Study Phase: Phase 1
Phase I Study of tTF-NGR in Patients With Recurrent or Refractory Malignant Tumors and Lymphomas Beyond All Standard Treatments
Phase I Study of tTF-NGR in Patients With Recurrent or Refractory Malignant Tumors and Lymphomas Beyond All Standard Treatments
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 2 Less Clinical Trials

151 Total Publications

Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
Journal: Leukemia & lymphoma
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schliemann's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile